INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
8. januar 2018 opdateret af: Incyte Corporation
A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma
A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.
Studieoversigt
Status
Afsluttet
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
8
Fase
- Fase 2
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Men and women, aged 18 years or older
- Histologically confirmed diagnosis of classical HL
- Must be relapsed or refractory after autologous stem cell transplant (ASCT) and/or 2 or more prior chemotherapy regimens
- Must have had prior treatment with brentuximab vedotin or not a candidate for treatment with brentuximab vedotin
- Eastern Cooperative Oncology Group (ECOG) 0 to 2
Exclusion Criteria:
- Laboratory parameters not within the protocol-defined range
- Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug.
- Received any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent).
- Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy
- Received autologous stem cell transplant within 28 days or allogeneic transplant within 3 months prior to first dose of study drug
- History of lymphoma involving the central nervous system
- Evidence of active or prior hepatitis infection.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: INCB040093 Monotherapy
INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
|
INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
|
|
Eksperimentel: INCB040093 and itacitinib (INCB039110) Combination Therapy
Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets.
The dose of itacitinib will be orally given once daily (QD).
Doses should be taken in the morning on an empty stomach if possible.
|
INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
The dose of itacitinib will be given orally once daily (QD).
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) as determined by the percentage of subjects achieving a partial response (PR) or complete response (CR)
Tidsramme: Measured every 9 weeks from baseline until progression (estimated to be 12 months)
|
Evaluate the efficacy of INCB040093 as monotherapy and when given in combination with itacitinib by assessing the objective response rate (ORR) determined by an independent review committee.
|
Measured every 9 weeks from baseline until progression (estimated to be 12 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants reporting adverse events in the monotherapy group
Tidsramme: every 3 weeks for the duration of participation in the study [estimated to be 12 months]
|
Safety and tolerability of INCB040093 as monotherapy in subjects with relapsed or refractory Hodgkin's lymphoma (HL) as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events
|
every 3 weeks for the duration of participation in the study [estimated to be 12 months]
|
|
Percentage of participants reporting adverse events in the combination therapy group
Tidsramme: every 3 weeks for the duration of participation in the study [estimated to be 12 months]
|
Safety and tolerability of INCB040093 when given in combination with itacitinib in subjects with relapsed or refractory Hodgkin's lymphoma (HL) as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events
|
every 3 weeks for the duration of participation in the study [estimated to be 12 months]
|
|
Percentage of subjects achieving a complete response (CR) determined by the independent review committee and based on standard response criteria
Tidsramme: Week 36 disease evaluation
|
Complete Response is determined by the independent review committee and based on standard response criteria defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria.
CR: Disappearance of all target and nontarget lesions.
|
Week 36 disease evaluation
|
|
To evaluate the duration of response (DOR)
Tidsramme: Week 36 disease evaluation
|
Duration of response is defined as the time from the first assessment showing response (CR or PR) determined by the independent review committee to the first documented disease progression determined by the independent review committee or death due to any cause, whichever occurs first.
|
Week 36 disease evaluation
|
|
To evaluate the progression-free survival (PFS)
Tidsramme: Week 36 disease evaluation
|
PFS was defined as the time from first dose to the first documented disease progression or relapse as assessed by independent review committee or death from any cause.
|
Week 36 disease evaluation
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. juni 2015
Primær færdiggørelse (Faktiske)
16. december 2016
Studieafslutning (Faktiske)
16. december 2016
Datoer for studieregistrering
Først indsendt
19. marts 2015
Først indsendt, der opfyldte QC-kriterier
27. maj 2015
Først opslået (Skøn)
28. maj 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
12. januar 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. januar 2018
Sidst verificeret
1. januar 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 40093-201
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .